Edwards Lifesciences (NY:EW)

90.47 -0.09 (-0.10%)

Delayed Quote Updated: 11:02 AM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Peering Into Edwards Lifesciences's Recent Short Interest ↗

June 14, 2022

Edwards Lifesciences's (NYSE:EW) short percent of float has risen 6.33% since its last report. The company recently reported that it has 5.15 million shares sold short, which is 0...

Via Benzinga

Here's How Much $1000 Invested In Edwards Lifesciences 15 Years Ago Would Be Worth Today ↗

June 13, 2022

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 16.51% on an annualized basis producing an average annual return of 22.72%. Currently, Edwards Lifesciences has a...

Via Benzinga

Where Edwards Lifesciences Stands With Analysts ↗

May 17, 2022

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Via Benzinga

7 Growth Stocks That Analysts Love Right Now ↗

May 17, 2022

These growth stocks are receiving buy ratings and significantly higher price targets from analysts, making them ideal names to consider.

Via InvestorPlace

Why Jim Cramer Prefers These 2 Semiconductor Stocks ↗

May 03, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said SoFi Technologies, Inc. (NASDAQ: SOFI) has been getting destroyed.

Via Benzinga

Edwards Lifesciences Clocks 10% Top-Line Growth In Q1; Forecasts Lower Than Expected Q2 Sales ↗

April 27, 2022

Via Benzinga

Medtech Giant Edwards Lifesciences Tumbles Despite First-Quarter Beat ↗

April 26, 2022

The medtech giant narrowly beat first-quarter sales and earnings views.

Via Investor's Business Daily

Earnings Scheduled For April 26, 2022 ↗

April 26, 2022

Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million.

Via Benzinga

Expert Ratings for Edwards Lifesciences ↗

April 13, 2022

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Via Benzinga

Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review ↗

April 29, 2022

The Nasdaq hit its lowest level since 2020. Apple and Facebook led key earnings.

Via Investor's Business Daily

If You Invested $100 In Edwards Lifesciences 20 Years Ago, Here's How Much You Would Have Today ↗

April 27, 2022

Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 14.71% on an annualized basis producing an average annual return of 21.87%. Currently, Edwards Lifesciences has a...

Via Benzinga

Recap: Edwards Lifesciences Q1 Earnings ↗

April 26, 2022

Edwards Lifesciences (NYSE:EW) reported its Q1 earnings results on Tuesday, April 26, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Via Benzinga

Market Briefing For Monday, April 25 ↗

April 25, 2022

It's clearly on the edge of the generals completing their retreat to join troops already in the trenches. Nevertheless the same variables prevail; it's hard to project any sustainable rallies.

Via Talk Markets

Where Edwards Lifesciences Stands With Analysts ↗

January 27, 2022

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:

Via Benzinga

Establishment Labs Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

April 20, 2022

Establishment Labs stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 92, up from 87 the day before.

Via Investor's Business Daily

Inspire Medical Systems Stock Scores Relative Strength Rating Upgrade ↗

April 20, 2022

Inspire Medical System stock reached an key technical benchmark, seeing its Relative Strength (RS) Rating jumping to 91.

Via Investor's Business Daily

Five Of The Best Chinese Stocks To Keep An Eye On

April 16, 2022

This year has been a stellar one for the Chinese stock market. After a year that saw the Shanghai Stock

Via Best Stocks

Pfizer Stock, Raytheon Lead 5 Stocks Near Buy Points ↗

April 16, 2022

Pfizer, Raytheon lead stocks shielded from geopolitics and rate hikes.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022 ↗

April 13, 2022

Upgrades

Via Benzinga

Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors ↗

April 09, 2022

Raytheon and Shell are just below buy points. They have good company.

Via Investor's Business Daily

7 Medical Device Stocks to Buy as Covid-19 Fears Fade ↗

April 05, 2022

With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks.

Via InvestorPlace

3 Top S&P 500 Stock Market Gainers Today: Medicals Lead As This Sector Reverses Hard ↗

April 01, 2022

Medical and gold stocks led the S&P 500. Transport stocks were big losers.

Via Investor's Business Daily

FDA Approves Edwards Lifesciences' Resilia Valve For Mitral Replacement Surgery ↗

March 31, 2022

The FDA has approved Edwards Lifesciences Corp's (NYSE: EW) Mitris Resilia valve, a tissue valve replacement specifically designed for the heart's mitral...

Via Benzinga

What 9 Analyst Ratings Have To Say About Edwards Lifesciences ↗

March 16, 2022

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Analyst Ratings For Edwards Lifesciences ↗

March 16, 2022

Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022 ↗

March 16, 2022

Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to...

Via Benzinga

This Foreboding Sign Looms Over Edwards Lifesciences's Chart ↗

March 14, 2022

If history is any guide, there may be trouble ahead for shares of Edwards Lifesciences (NYSE:EW). A so-called "death cross" has formed on its chart and, not surprisingly, this...

Via Benzinga

The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗

January 31, 2022

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022 ↗

February 02, 2022

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...

Via Benzinga

Stock Market Whipsaws Lower On Hawkish Fed, Tesla; Apple, Microsoft Earnings Strong: Weekly Review ↗

January 28, 2022

Microsoft and Apple earnings were strong, but the correction is getting worse.

Via Investor's Business Daily

< Previous 1 2

...

17 18 19 20 21 22 23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.